News & Updates
Showing Multidisciplinary articles
Showing

Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.

Polymeric immunoglobulin receptor boosts cancer stemness, tumorigenesis in HCC patients
Extracellular vesicles enriched with the polymeric immunoglobulin receptor molecule contributes to tumorigenesis and cancer stemness in patients with hepatocellular carcinoma (HCC), reports a recent study.

IV steroids may do more harm than good in older-onset ulcerative colitis
In patients with older-onset ulcerative colitis (UC), treatment with intravenous (IV) steroids appears to be less effective and is associated with higher risks of surgery and adverse events relative to patients with younger-onset disease, a study has found.

TYK2 inhibitor for psoriatic arthritis clears phase II trial
In the treatment of patients with psoriatic arthritis, the use of the selective TYK2 inhibitor deucravacitinib appears to be effective and well tolerated, leading to greater improvements in American College of Rheumatology (ACR) domains, enthesitis endpoints, and multiple patient-reported, psoriasis-related outcomes relative to placebo, as shown in the results of a phase II trial.




